Actuate Therapeutics Inc (ACTU) Revenue History
Annual and quarterly revenue from 2022 to present
ACTU Revenue Over Time (2022–2025)
ACTU Revenue Growth History
- FY2022 revenue growth
- N/A
- FY2023 revenue growth
- N/A
- FY2024 revenue growth
- N/A
- FY2025 revenue growth
- N/A
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $0 | — |
| Q4 2025 | $0 | — |
| Q3 2025 | $0 | — |
| Q2 2025 | $0 | — |
| Q1 2025 | $0 | — |
| Q4 2024 | $0 | — |
| Q3 2024 | $0 | — |
| Q2 2024 | $0 | — |
ACTU Revenue Analysis (2022–2025)
Current Revenue & Growth
As of June 13, 2026, Actuate Therapeutics Inc (ACTU) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q1 2026) recorded $0 in revenue
Historical Growth Trajectory
ACTU's historical revenue data shows various trends over time.
Peer Comparison
Compared to Healthcare sector peers — including TPVG, AGIO (+78.3% YoY), and IDYA (+3118.1% YoY). Compare ACTU vs TPVG →
ACTU Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
 ACTUCurrent | $0 | - | - | - | |
 TPVG | $97M | - | - | 77.9% | |
 AGIO | $54M | +78.3% | - | -873.9% | |
 IDYA | $219M | +3118.1% | +62.1% | -72.8% |
ACTU Historical Revenue Data (2022–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $0 | - | $0 | - | $-22,495,312 | - |
| 2024 | $0 | - | $0 | - | $-25,160,734 | - |
| 2023 | $0 | - | $0 | - | $-24,973,829 | - |
| 2022 | $0 | - | $0 | - | $-20,206,807 | - |
What if you invested $1,000 in ACTU back in 2022?
Total return with dividends reinvested · 4+ years of data
Calculate ReturnsHow much would $100/month in ACTU be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs ACTU Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationACTU vs LLY — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Eli Lilly and Company.
Compare NowACTU — Frequently Asked Questions
Quick answers to the most common questions about buying ACTU stock.
Is ACTU's revenue growth accelerating or slowing?
ACTU TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.
What is ACTU's revenue history from 2022 to 2026?
Actuate Therapeutics Inc (ACTU) revenue history spans 2022 to 2026. TTM revenue as of 2026 is $0.00, growing at N/A YoY. The 5-year CAGR is N/A. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is ACTU's long-term revenue growth rate (CAGR)?
Actuate Therapeutics Inc's 5-year revenue CAGR of N/A reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of N/A is in line with this long-term average. CAGR is the most reliable measure of sustained revenue momentum for ACTU.
Why does ACTU's quarterly revenue fluctuate?
ACTU quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Actuate Therapeutics Inc's revenue data from 2022 to 2026 shows full historical quarterly detail on this page.
How is ACTU's revenue distributed by segment?
ACTU reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does ACTU's revenue compare to industry peers?
Actuate Therapeutics Inc (ACTU) with TTM revenue of $0.00 and N/A YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.